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r spirat ry　dis ress　syndrome　or　chronic　pulmonary
hypertension．　The　prostanoid　PGI2　doses，　however，
possess a　v ry　short　biological　half二lifb（2－3　min）at　a
physiol gical　pH，　and　after　inhalation　of　aerosolized
PGI2 the　pulmonary　vasodilator　ef艶ct　is　lost　within
＜30min　b th　under　experimental　conditions　and
when　tested　in　patients（Olschewski　et　al．，1996；
Schermuly　et　al．，1999）．　In　intact　rabbits　with　acute
pulmonary hypertension（Schermuly　et　al．，1999），
subthreshold　intravenous　doses　of　nonselective　PDE3，
PDE4，　and　PDE5　i hibi七〇rs　have　been　noted　to　aug－
ment　a d　prolong　the　pulmonary　vasodilator　response
to　inhaled　PGI2　while　li皿iting　the　hypotensive　effbct
in　the　pulmonary circulation．　Recently，　a　prior　ad－
ministration　of　subthreshold　doses　of　the　clinically　ap－
proved　PDE　inhibitors　theophylline，　dipyridamole，
and　 pe toxifylline　　via　　the　　intravascular　　or
inhalational　 oute，　which　did　not　itself　influence　pu1－
monary　hemodynamics，　caused　more　than　a　doubling
of　the　imm diate　drop　in　pulmonary　arterial　pressure
that　occurred　in　response　to　PGI2，　and　also　a　marked
pr longation　of　the　post－PGI2　vasorelaxation　to＞60
min（all the　PDE　inhibitors　being　ef｛bctive　when　given
route）（Schermuly　et　a1．，2001）．　Thus，　coaerosoliza七ion
of　PGI2　and　PDE　inhibitors　should　be　considered　as　a
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postulated　therapeutic
hypertension．
strategy　against　pulmonary
Subarachnoid　hemorrhage
　　　　It　is　well　established　that　endothelium－
dependent，　NO－induced　cerebral　vasodilator　re－
sponses　are　impaired　in　a　variety　of　animal　models　of
subarachnoid　hemorrhage（SAH）（Kanamaru　et　aL，
1989；Kim　et　al．，1989；Edwards　et　aL，1992；Sobey　et
aL，1996），　and　also　in　patients　with　SAH（Hatake　et
al．，1992；Onoue　et　a1．，1995）．　This　may　be　partly　due
to　reduced　NO　release　resulting　fをom　damaged　to　en－
dothelial　cells（Smith　et　al．，1985；Clower　et　aL，1994），
but　importantly　it　seems　that　other　mechanisms　may
also　contribute．　For　example，　numerous　studies　have
reported　that　the　cerebral　vasodilator　responses　to
NO－donor　drugs　are　also　impaired　after　SAH（Kim　et
al．，1989；Onoue　et　al．，1995；Zuccarello　et　al．，1996；
Yamamoto　et　al．，1997），　suggesting　that　the　respon－
siveness　of　cerebral　vascular　smooth　muscle　to　NO　is
altered．　Moreover，　the　vasodilator　responses　to　ACh，
sodium　nitroprusside（SNP），　and　low　concentrations
of　zaprinast，　an　inhibitor　of　PDE5，　are　all　impaired　in
SAH　rats（Sobey　and　Quan，1999）．　In　contrast，　the
vasodilator　responses　to　adenosine　and　8Br－cGMP
were　similar　between　control　and　SAH　rats，　and　the
vasoconst亘ctor　response　to　ODQ，　an　inhibitor　of　solu－
ble　guanyla七e　cyclase，　were　unaf丘cted　by　SAH．　In　the
presence　of　zaprinast，　the　responses　to　ACh　and　SNP
were　similar　between　control　and　SA且rats．　In　a　ca－
nille　model　of　SAH，　PDE5　activity　was　increased　to
above　control　levels　within　the　basilar　artery　seven
days　after　SAH，　and　the　PDE5　expression　was　most
prominent　in　SMCs　fbllowing　SAH（Inoha　et　al．，
2002）．Thus，　an　increased　rate　of　cGMP　hydrolysis　by
PDE5　may　be　a　m司or　factor　contributing　to　the　im－
pai㎜ent　of　NO－mediated　cerebral　vasodilation　aRer
SAH．　On　the　other　hand，　in　a　canine　model　of　acute
cerebral　vasospasm，　BRL61063，　rolipram，　and
denbufylline，　a　selective　inhibitor　of　PDE4，　reversed
e　basil r　artery　spasm　produced　by　autologous
blood　without　altering　mean　arterial　blood　pressure、
In contrast，　prolonged　treatment　with　BRL61063
血iled　to　alter　the　development　of　basilar　spasm　in　two
canine　 emorrhage　models　of　chronic　cerebral
vaso pasm．　Denbufylline－induced　relaxation　in　vitro
was　also　significalltly　impaired　in　basilar　arteries　ob－
t in d丘om　a　model　of　chronic　vasospasm．　In　conclu－
sion，　PDE4　appears　to　be　the　predominant　isozyme
regulating　vascular　tone　via　cAMP　hydrolysis　in　cere－
bral　ve sels（Willette　et　al．，1997）．　Further　investiga－
tion　is　needed　to　determine　whether　inhibition　of
PDEs　activi y　might　be　a　usef皿1　approach　in　patients
with　SAH．
　　　　I 　conclusion，　we　believe　that　manipulation　of　the
activities of　PDEs　within　vascular　system　may　have
considerable　therapeutic　potential．　Once　the　fbll　rep－
ertoire　of　the　PDEs　expressed　within　the　vascular　sys－
tem　has　been　established，　it　should　not　be　long　befbre
n w generations　of　selective　PDE　inhibitors　are　avai1－
able　to manipulate　vascular　cell　responses．
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